drugset / Trial / NCT00975481
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
RandomizedCrossoverDouble-blind
Summary
Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).
Timeline
- Start
- 2009-10
- Primary completion
- 2010-02
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alprazolam | Small molecule | 1 mg | Oral |
| Comparator | Alprazolam | Small molecule | 3 mg | Oral |
| Subject | Latrepirdine | Small molecule | 20 mg | Oral |
| Subject | Latrepirdine | Small molecule | 40 mg | Oral |
| Subject | Latrepirdine | Small molecule | 60 mg | Oral |